Lv5
985 积分 2021-08-08 加入
Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease
2天前
已完结
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial
2天前
已完结
Efficacy and safety of oral Pcsk9 inhibitors: insights from a meta-analysis of RCTs
2天前
已完结
Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis
2天前
已完结
Oral PCSK9 inhibitors as an emerging frontier in lipid management: A meta-analysis
2天前
已完结
Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia
2天前
已完结
Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia
2天前
已关闭
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
3天前
已完结
Safety and Efficacy of Oral PCSK9 Inhibitors in Hypercholesterolemia: A Systematic Review and Network Meta-Analysis
3天前
已完结
Phase 3 study results for oral PCSK9 inhibition with enlicitide
3天前
已完结
皖公网安备34019202002308
